The share price of Irish biotech firm Prothena (Nasdaq: PRTA) has spiked over 10% on news that the company has finalized a major partnership with industry giant Celgene (Nasdaq: CELG).
The deal, which is worth up to $2 billion to the Dublin-headquartered company, is focused on three proteins: tau, TDP-43 and another, undisclosed target, each of which is implicated in the pathogenesis of neurodegenerative diseases such as Alzheimer's.
Prothena will receive $150 million upfront, and US Securities and Exchange Commission (SEC) documents indicate that they will eligible for up to a further $562 million per program. Of the initial $150 million, $50 million will include a mass purchase of Prothena shares – 1.2 million in total at $42.57 per share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze